Projecting future drug expenditures - 2012

American Journal of Health-System Pharmacy

Volumn 69, Issue 5, 2012, Pages 405-421

  Hoffman, James M ^a,b   Li, Edward ^c   Doloresco, Fred ^d,e   Matusiak, Linda ^f   Hunkler, Robert J ^f   Shah, Nilay D ^g,h   Vermeulen, Lee C ^i,j   Schumock, Glen T ^k,l  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

^d School of Pharmacy and Pharmaceutical Sciences Buffalo   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f IQVIA   (United States)

^g Cleveland Clinic Lerner   (United States)

^h MAYO CLINIC   (United States)

ⁱ University of Wisconsin Health   (United States)

^j UNIVERSITY OF WISCONSIN MADISON   (United States)

^k Department of Pharmacy Practice ^*  (United States)

^l UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

Ambulatory care; Costs; Drug distribution; Drugs; Economics; Hospitals; Prescriptions; Product development

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ACLIDINIUM BROMIDE; AMLODIPINE PLUS ATORVASTATIN; APIXABAN; ATORVASTATIN; AXITINIB; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CLOPIDOGREL; CRIZOTINIB; DABIGATRAN; ESCITALOPRAM; EXEMESTANE; FENOFIBRATE; IPILIMUMAB; LINACLOTIDE; LUCINACTANT; PEGINESATIDE; PIXANTRONE; PRASUGREL; RIDAFOROLIMUS; RIVAROXABAN; TALIGLUCERASE ALFA; THREO 3,4 DIHYDROXYPHENYLSERINE; TICAGRELOR; UNINDEXED DRUG; VANDETANIB; VEMURAFENIB; VINCRISTINE SULFATE; VISMODEGIB;

ANTICOAGULANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG COST; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH INSURANCE; HOSPITAL MANAGEMENT; HOSPITAL UTILIZATION; ONCOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 84857591730     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp110697     Document Type: Review

References (80)

1. McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011; 306: 402-9.
2. Executive summary: Pharmacy Practice Model Summit. Am J Health-Syst Pharm. 2011; 68:1079-85.
3. The consensus of the Pharmacy Practice Model Summit. Am J Health-Syst Pharm. 2011; 68:1148-52.
4. American College of Healthcare Executives. Annual survey. www.ache.org/Pubs/Releases/2011/topissues.cfm (accessed 2011 Nov 23).
5. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2009. Am J Health-Syst Pharm. 2009; 66:237-57.
6. Cutler DM. The demise of the blockbuster? N Engl J Med. 2007; 356:1292-3. (Pubitemid 46513294)
7. Bronstein D. Concerns emerge over ipilimumab pricing and restricted distribution. www.pharmacypracticenews.com/ViewArticle.aspx?d= Web%2BExclusives&d-id=239&i=July%2B2011&i-id=749&a-id=18435 (accessed 2011 Dec 1).
8. Comer B. AstraZeneca signs exclusive distribution deal for vandetanib. http://blog.pharmexec.com/2011/04/27/astrazeneca-signs-exclusive-distribution- deal-for-vandetanib (accessed 2011 Dec 1).
9. Church S. Abiraterone now approved as Zytiga by the FDA in castrate resistant prostate cancer. http://pharmastrategyblog.com/2011/04/abiraterone- now-approved-as-zytiga-by-the-fda-in-castrate-resistant-prostate-cancer.html (accessed 2011 Dec 1).
10. Petrochko C. FDA OKs late-stage melanoma drug. www.medpagetoday.com/ PublicHealthPolicy/FDAGeneral/28083 (accessed 2011 Dec 1).
11. Nordqvist C. Adcetris may cost $4,500 per vial, or over $100,000 for a course of lymphoma treatment. www.medicalnewstoday.com/ articles/233141.php (accessed 2011 Dec 1).
12. Lichtenfeld L. Crizotinib approval for lung cancer shows our miracles aren't getting less expensive. www.cancer.org/AboutUs/DrLensBlog/post/2011/08/ 30/Crizotinib-Approval-For-Lung-Cancer-Shows-Our-Miracles-Arent-Getting-Less- Expensive.aspx (accessed 2011 Dec 1).
13. Carpenter D, Zucker EJ, Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008; 358:1354-61. (Pubitemid 351468412)
14. Medco. 2011 drug trend report. www.drugtrendreport.com (accessed 2011 Oct 14).
15. Protalix Biotherapeutics. Protalix Biotherapeutics announces FDA accepts for review complete response resubmission for taliglucerase alfa and assigns PDUFA date. http://phx.corporateir.net/phoenix.zhtml?c=101161&p= irolnewsArticle&ID=1597375&highlight= (accessed 2011 Dec 1).
16. Bristol-Myers Squibb. FDA accepts ELIQUIS (apixaban) new drug application for review for the prevention of stroke and systemic embolism in patients with atrial fibrillation. www.businesswire.com/portal/site/bms/index.jsp?ndmViewId= news-view&ndm ConfigId=1015992&newsId=20111129005482&newsLang=en (accessed 2011 Dec 1).
17. Discovery Labs submits SURFAXIN complete response to FDA. Discovery Labs press releases Web site. www.discoverylabs.com/2011pr/090611-PR.pdf (accessed 2011 Dec 1).
18. Affymax. Affymax announces FDA advisory committee to review peginesatide. www.investors.affymax.com/releasedetail.cfm?ReleaseID=617226 (accessed 2011 Dec 1).
19. Onyx Pharmaceuticals. Onyx Pharmaceuticals announces FDA acceptance of new drug application for carfilzomib for the treatment of relapsed and refractory multiple myeloma. www.onyx-pharm.com/news/onyx-pharmaceuticals- announces-fda-acceptance-of-new-drug-application-for-carfilzomib-for-the- treatment-of-relapsed-and-refractory-multiple-myeloma (accessed 2011 Dec 1).
20. Forest Laboratories. Forest and Almirall announce submission of new drug application for aclidinium bromide for the treatment of chronic obstructive pulmonary disease (COPD). www.frx.com/news/PressRelease.aspx?ID=1581023 (accessed 2011 Dec 1).
21. Pfizer. Pfizer files with the FDA for review of axitinib for patients with advanced renal cell carcinoma. www.pfizer.com/news/press-releases/pf izer-press-release-archive.jsp#guid=20110705006342en&source= RSS-2011&page=7 (accessed 2011 Dec 1).
22. Chelsea Therapeutics. Chelsea Therapeutics announces FDA acceptance of NDA for filing and designation of priority review of NORTHERA(TM) for the treatment of symptomatic NOH. http://files.shareholder.com/downloads/CHTP/ 1526676941x0x519235/ec53bebb-f931-4dfb-82a1-241f8d80a7fd/CHTP-News-2011-11-17- News-Releases.pdf (accessed 2011 Dec 1).
23. Talon Therapeutics. Talon Therapeutics'new drug application for Marqibo(R) accepted for filing by the United States Food and Drug Administration. http://files.shareholder.com/downloads/HNAB/1526677407x0x502902/ d4c092d4-a948-49b8-b210- e43cd8908f28/TLON-News-2011-9-27-General-Releases.pdf (accessed 2011 Dec 1).
24. Roche. FDA accepts Roche's new drug application for vismodegib in advanced form of skin cancer. www.roche.com/media/media-releases/med-cor-2011- 11-09.htm (accessed 2011 Dec 1).
25. Forest Laboratories. Ironwood and Forest announce linaclotide new drug application for the treatment of irritable bowel syndrome with constipation and chronic constipation accepted for FDA review. www.frx.com/news/PressRelease. aspx?ID=1620221 (accessed 2011 Dec 1).
26. Cell Therapeutics. Cell Therapeutics resubmits pixantrone NDA to FDA for consideration of accelerated approval. http://investors.celltherapeutics.com/ phoenix.zhtml?c=92775&p=irol-newsArticle&ID=1620829&highlight= (accessed 2011 Dec 1).
27. Merck. FDA accepts new drug application filing for ridaforolimus ImI. www.merck.com/newsroom/newsrelease-archive/research-and-development/2011-1005. html (accessed 2011 Dec 1).
28. Rogers EM. Diffusion of innovations, 4th ed. New York: Free Press; 1995.
29. Hoffman JM, Shah ND, Vermeulen LC et al. Projecting future drug expenditures - 2006. Am J Health-Syst Pharm. 2006; 63: 123-38. (Pubitemid 43100358)
30. Drugs@FDA. Label and approval history for Pradaxa (dabigatran). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist (accessed 2011 Dec 6).
31. Drugs@FDA. Label and approval history for Xarelto (rivaroxaban). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Label-ApprovalHistory#apphist (accessed 2011 Dec 6).
32. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363:2499-510.
33. Mega JL, Braunwald E, Wiviott SD et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. Epub ahead of print. 2011 Nov 13 (DOI 10.1056/NEJMoa1112277).
34. Cohen AT, Spiro TE, Buller HR et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011; 31:407-16.
35. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-52.
36. Pradaxa (dabigatran etexilate mesylate): drug safety communication - safety review of post-market reports of serious bleeding events. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm282820.htm (accessed 2011 Dec 19).
37. Nutescu EA, Pickard AS, Blackburn JC et al. Impact of oral direct thrombin inhibitors on anticoagulation clinics. Pharmacotherapy. 2004; 24:1204-12. (Pubitemid 39128844)
38. Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011; 31:1175-91.
39. Cavallari LH, Shin J, Perera MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy. 2011; 31:1192-207.
40. Johnson JA, Gong L, Whirl-Carrillo M et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90:625-9.
41. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361:1045-57.
42. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001-15. (Pubitemid 350106708)
43. Ticagrelor (Brilinta) - better than clopidogrel (Plavix)? Med Lett Drugs Ther. 2011; 53:69-70.
44. Hamm CW, Bassand JP, Agewall S et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. Epub ahead of print. 2011 Sep 21 (DOI 10.1093/eurheartj/ehr236).
45. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011; 58:2550-83.
46. Scott SA, Sangkuhl K, Gardner EE et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011; 90:328-32.
47. Azzoli CG, Temin S, Aliff T et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011; 29:3825-31.
48. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:2666-76.
49. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28:3239-47.
50. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29:1252-60.
51. Regulations.gov. FDA/Center for Drug Evaluation and Research (CDER) to Genentech, Inc. - letter. www.regulations.gov/#!documentDetail;D=FDA-2010-N- 0621-0001 (accessed 2011 Nov 22).
52. Sekeres MA. The Avastin story. N Engl J Med. 2011; 365:1454-5.
53. Food and Drug Administration. Proposal to withdraw approval for the breast cancer indication for Avastin (bevacizumab) - decision of the Commissioner. www.fda.gov/downloads/NewsEventsNewsroom/UCM280546.pdf (accessed 2011 Nov 18).
54. IMS Health National Sales Perspectives. Analysis conducted by the authors. Analysis conducted November 2011.
55. Carlson RW, Allred DC, Anderson BO et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011; 9:136-222.
56. Medco. Estimated dates of possible first time generic/ Rx-to-OTC market entry. www.medcohealth.com/art/corporate/anticipatedfirsttime-generics.pdf (accessed 2011 Dec 6).
57. Hughes S. Generic atorvastatin now available in US 2011. www.theheart.org/article/1322545.do (accessed 2011 Dec 2).
58. Edney A, Narayan A. Ranbaxy's Lipitor copy in U.S. stores threatens Pfizer sales. www.bloomberg.com/news/2011-12-01/ranbaxy-wins-approval-to-sell- generic-version-of-pfizer-s-lipitor-medicine.html (accessed 2011 Dec 2).
59. Pfizer. Lipitor For You program - impor tant safety information. www.lipitor.com/patients/lipitorforyou.aspx (accessed 2011 Nov 20).
60. Jackevicius CA, Chou MM, Ross JS et al. Generic atorvastatin and health care costs. N Engl J Med. Epub ahead of print. 2011 Dec 7 (DOI 10.1056/NEJMp1113112).
61. Doloresco F, Fominaya C, Schumock GT et al. Projecting future drug expenditures - 2011. Am J Health-Syst Pharm. 2011; 68:921-32.
62. Drugs@FDA. Label and approval history (enoxaparin sodium [preservative free]). www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Overview&DrugName=ENOXAPARIN%20SODIUM%20%28PRESERVATIVE%20FREE%29 (accessed 2011 Nov 30).
63. Ready T. FDA approves first generic versions of levofloxacin. www.medscape.com/viewarticle/745007 (accessed 2011 Nov 30).
64. Food and Drug Administration. Drugs@FDA. www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm (accessed 2011 Dec 1).
65. Kesselheim AS, Murtagh L, Mello MM. "Pay for delay" settlements of disputes over pharmaceutical patents. N Engl J Med. 2011; 365:1439-45.
66. Ending drug companies' pay-for-delay deals. www.washingtonpost.com/ opinions/ending-drug-companies-pay-for-delay-deals/2011/10/24/gIQAxyfjDM-story. html (accessed 2011 Dec 1).
67. Cherici C, McGinnis P, Russell W et al. Buyer beware: drug shortages and the gray market. www.premierinc.com/about/news/11-aug/Gray-Market/Gray-Market- Analysis-08152011.pdf (accessed 2011 Dec 2).
68. Kaakeh R, Sweet BV, Reilly C et al. Impact of drug shortages on U.S. health systems. Am J Health-Syst Pharm. 2011; 68:1811-9.
69. Harris G. Obama tries to speed response to shortages in vital medicines. www.nytimes.com/2011/10/31/health/policy/medicine-shortages-addressed-in-obama- executive-order.html (accessed 2011 Nov 23).
70. Herper M. Cancer doctors fear chemo drug shortage. www.forbes.com/2008/ 12/16/cancer-pharmaceuticals-leucovorin-biz-healthcare-cx-mh-1216shortage.html (accessed 2011 Nov 3).
71. Food and Drug Administration. Current drug shortages. www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm050792.htm (accessed 2011 Nov 3).
72. American Society of Clinical Oncology. Clinical alert - leucovorin shortage. www.asco.org/ascov2/Department%20Content/ Cancer%20Policy%20and%20Clinical%20Affairs/Downloads/Cancer%20Policy%20News/ Cancer%20Policy%20Alert/Leucovorin%20Alert%208-5-2010.pdf (accessed 2011 Nov 21).
73. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T et al. Colon cancer. J Natl Compr Canc Netw. 2011; 9:1238-90.
74. Goldberg P. Drug shortage on boon for levoleucovorin; price is 60 times higher than leucovorin. Cancer Lett. 2009; 35:1-2.
75. Zelenetz AD, Ahmed I, Braud EL et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011; 9(suppl 4):S1-22.
76. Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011; 9:934-42.
77. Hoffman JM, Doloresco F, Vermeulen LC et al. Projecting future drug expenditures - 2010. Am J Health-Syst Pharm. 2010; 67:919-28.
78. Keehan SP, Sisko AM, Truffer CJ et al. National health spending projections through 2020: economic recovery and reform drive faster spending growth. Health Aff. 2011; 30:1594-605.
79. Express Scripts. Drug trend report. www.express-scripts.com/research/ studies/drugtrendreport/2010/dtrFinal.pdf (accessed 2011 Dec 6).
80. American Society of Health-System Pharmacists. ASHP guidelines on medication cost management strategies for hospitals and health systems. Am J Health-Syst Pharm. 2008; 65:1368-84.